tiprankstipranks
Advertisement
Advertisement

ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position

Story Highlights
  • ProQR reported a €13.4 million loss for Q1 2026 as revenue fell and operating costs remained high.
  • The company ended March 31, 2026 with €81.1 million in cash, reduced equity and limited financial debt.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position

Meet Samuel – Your Personal Investing Prophet

ProQR ( (PRQR) ) just unveiled an announcement.

ProQR reported unaudited financial results for the three months ended March 31, 2026, in a Form 6-K filed on May 12, 2026, along with a business update for the period. The company posted a loss of €13.4 million as revenue declined year-on-year, while it maintained a strong cash position of €81.1 million and continued to carry substantial deferred income and lease liabilities, underscoring ongoing R&D investment and a still-sizeable funding runway.

Equity attributable to shareholders fell to €37.6 million from €49.4 million at year-end 2025, reflecting the first-quarter loss and currency effects. Despite the widening operating loss versus the prior-year quarter, ProQR reported no borrowings on its non-current balance sheet and modest current borrowings, positioning the company with limited financial debt as it advances its research programs and manages its collaboration-related obligations.

The most recent analyst rating on (PRQR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.

Spark’s Take on PRQR Stock

According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.

The score is held back primarily by weak financial performance (persistent losses and renewed heavy cash burn) and a negative P/E that underscores lack of profitability. Technicals provide some support due to improving price momentum above key moving averages.

To see Spark’s full report on PRQR stock, click here.

More about ProQR

ProQR Therapeutics N.V. is a biotechnology company based in Leiden, the Netherlands, focused on developing RNA-based therapies. The firm targets genetic disorders and reports as a foreign private issuer in the U.S. capital markets, reflecting its international investor base and regulatory profile.

Average Trading Volume: 547,211

Technical Sentiment Signal: Sell

Current Market Cap: $166.5M

For detailed information about PRQR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1